Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Gewirtz

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Pharmacopsychiatry|July 1, 1993
Selegiline for neuroleptic-induced parkinsonismG R Gewirtz, Z Sharif, J L Cadet, et al.
The American Journal of Psychiatry|August 1, 1988
Occult thyroid dysfunction in patients with refractory depressionG R Gewirtz, D Malaspina, J A Hatterer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1994
BMY 14802, a sigma receptor ligand for the treatment of schizophreniaG R Gewirtz, J M Gorman, J Volavka, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Pharmacopsychiatry|July 1, 1993
Selegiline for neuroleptic-induced parkinsonismG R Gewirtz, Z Sharif, J L Cadet, et al.
The American Journal of Psychiatry|August 1, 1988
Occult thyroid dysfunction in patients with refractory depressionG R Gewirtz, D Malaspina, J A Hatterer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 1, 1994
BMY 14802, a sigma receptor ligand for the treatment of schizophreniaG R Gewirtz, J M Gorman, J Volavka, et al.
Pageof 1